Trial Profile
A Phase 1, Open-Label Study of the Absorption, Distribution, Metabolism and Excretion of 14C-Labeled IPI-145 and the Absolute Bioavailability of IPI-145 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2021
Price :
$35
*
At a glance
- Drugs Duvelisib (Primary) ; Duvelisib (Primary) ; Duvelisib (Primary)
- Indications Allergic asthma; Haematological malignancies; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Secura Bio
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Apr 2013 New trial record